Clinical Trials Browser

NIH × Recurrence × Sorafenib × Clear all

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT01851408 2015-04-15

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma, Recurrence

Clinical Trials

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma